Utilizing mononuclear cells (containing >75% AML blasts) from 6 samples of bone marrow aspirate (BMA) or peripheral blood (PB) AML cells expressing MLL1-FP or mtNPM1 (oncoplot of co-mutations in Supplementary Fig. S5), we found that, treatment with ziftomenib (over control) significantly increased loss of viability, more so in AML expressing MLL1-FP than mtNPM1 (Fig. 1E). The gene discussed is KMT2A; the disease is acute myeloid leukemia.